Dato-DXd

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Breast CancerNon-Small Cell Lung CancerOvarian CancerTriple-Negative Breast CancerUrothelial CancerTransitional Cell Carcinoma

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

1

Dato-DXd

AstraZeneca

Phase 3

42

Blenoxane

Bristol-Myers Squibb

Preclinical

13

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

14

Tianeptine

Pfizer

Preclinical

15

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

16

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

17

Metfomin

UUniversity of Texas Southwestern Medical Center

Preclinical

18

Bisphosphonate

Amgen

Preclinical

29

Naltrexone/bupropion

Novo Nordisk

Preclinical

110

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

1Show 21 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer4 trials

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Recruiting·AstraZeneca·Phase 3·NCT06417814·744 enrolled

A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)

Recruiting·AstraZeneca·Phase 2·NCT05061550·630 enrolled

A Phase 1/2 Trial of Ivonescimab With Dato-DXd or Osimertinib in Patients With Metastatic EGFR-mutant Non-small Cell Lung Cancer That Progressed on EGFR TKI Therapy

Recruiting·MMemorial Sloan Kettering Cancer Center·Preclinical·NCT07535437·66 enrolled

Show 1 more trial

An Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumour Activity of Novel Combinations in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (LIBRA)

Recruiting·AstraZeneca·Phase 2·NCT07098338·278 enrolled

Breast Cancer4 trials

A Phase IIIb, Open-label, Multinational Study Assessing the Efficacy and Safety of Dato-DXd Treatment in Patients With HRpositive, HER2 IHC 0, Locally Advanced Inoperable or Metastatic Breast Cancer Refractory to Endocrine Therapy (TROPION-Breast06)

Recruiting·AstraZeneca·Phase 3·NCT07205822·100 enrolled

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

Active, not recruiting·AstraZeneca·Phase 3·NCT05104866·732 enrolled

A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

Recruiting·AstraZeneca·Phase 3·NCT06103864·625 enrolled

Show 1 more trial

A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001; TROPION-Breast04)

Active, not recruiting·AstraZeneca·Phase 3·NCT06112379·1,902 enrolled

Triple-Negative Breast Cancer3 trials

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

Active, not recruiting·AstraZeneca·Phase 3·NCT05374512·644 enrolled

A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer

Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 1/2·NCT06508216·50 enrolled

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

Active, not recruiting·AstraZeneca·Phase 3·NCT05629585·1,174 enrolled

Solid Tumor1 trial

A Phase 1b, Multicenter, Open-Label Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

Active, not recruiting·Daiichi Sankyo·Phase 1·NCT06244485·210 enrolled

Urothelial Cancer1 trial

A Randomized, Open-Label, Phase 2/3 Study of Datopotamab Deruxtecan (Dato-DXd) Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) Who Progressed During or After Enfortumab Vedotin (EV) Plus Pembrolizumab Combination Treatment TROPION-Urothelial03 (TU03)

Recruiting·Daiichi Sankyo·Preclinical·NCT07129993·630 enrolled

2 more indications

Ovarian Cancer1 trial

A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Active, not recruiting·Daiichi Sankyo·Preclinical·NCT04644068·702 enrolled

Transitional Cell Carcinoma1 trial

A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma

Recruiting·AstraZeneca·Phase 3·NCT07720284·915 enrolled

Details

Drug Info

Related News